Epileptic seizure

NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy Treatment

Retrieved on: 
Monday, March 9, 2020
Biotechnology, Medical devices, Health, Science, Research, Neurotechnology, Medicine, Organ systems, Neuroscience, Neuroprosthetics, Responsive neurostimulation device, Electrotherapy, Medical devices, Neuromodulation, RNS, Epilepsy, Epileptic seizure, the RNS® System, NeuroPace

Im pleased that we have removed a potential barrier to treatment and increased the number of patients who can benefit from this life-changing therapy.

Key Points: 
  • Im pleased that we have removed a potential barrier to treatment and increased the number of patients who can benefit from this life-changing therapy.
  • Treatment with the RNS System has been shown in a real-world, multi-center retrospective study to deliver outcomes never before seen with any neuromodulation device for epilepsy.
  • The RNS System is the worlds only closed-loop brain-responsive neurostimulation system designed to prevent seizures at their source.
  • The companys first product, the RNS System, is the only FDA-approved brain-responsive neurostimulator for the treatment of focal onset refractory epilepsy.

Neurogene Joins Behind the Seizure® Program, Sponsors Genetic Testing for Children with Seizures

Retrieved on: 
Monday, February 10, 2020
Health, Consumer, Genetics, Children, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Health, Rare diseases, Medical genetics, Lipid storage disorders, Epileptic seizure, RTT, Genetic testing, Batten disease, Behind the Seizure®, Neurogene Inc.

With support from Neurogene, Behind the Seizure will allow healthcare providers to order no-cost genetic testing for any child under the age of eight who has had an unprovoked seizure.

Key Points: 
  • With support from Neurogene, Behind the Seizure will allow healthcare providers to order no-cost genetic testing for any child under the age of eight who has had an unprovoked seizure.
  • Identifying patients is a critical step on the road to treating rare genetic diseases, said Rachel McMinn, Ph.D., Neurogenes Founder and Chief Executive Officer.
  • Increasing access to genetic testing may help increase diagnosis of CLN5 and CLN7, two types of Batten disease in which unprovoked seizures can present later than other forms of Batten Disease.
  • Behind the Seizure is an innovative, cross-company collaboration designed to increase access to genetic testing for children who experience unprovoked seizures in childhood in the United States and Canada.

GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex

Retrieved on: 
Monday, February 3, 2020
Organ systems, Health, Medicine, Rare diseases, Epilepsy, Lennox–Gastaut syndrome, Anticonvulsants, Tuberous sclerosis, Cannabidiol, Dravet syndrome, Epileptic seizure, GW Pharmaceuticals

The sNDA seeks to expand the Epidiolex label to include the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic condition.

Key Points: 
  • The sNDA seeks to expand the Epidiolex label to include the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic condition.
  • Epidiolex is currently approved in the U.S. to treat seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome and has been granted Orphan Drug Designation from theFDAfor the treatment of TSC.
  • We look forward to working with the FDA toward an expected approval later this year."
  • A supplemental New Drug Application (sNDA) has been submitted to the FDA for the treatment of seizures associated with tuberous sclerosis complex (TSC).

Epileptic Seizure Monitor Alarm System Market, 2028 - Challenges and Opportunity Worldwide; Key Players Profiled: Empatica, Emfit, Alert-it, Vahlkamp, Danish Care and Medpage | Radiant Insights, Inc.

Retrieved on: 
Monday, January 20, 2020
Medicine, Clinical medicine, Epileptic seizure, RTT, Health, Epilepsy

The important motivators of the Epileptic Seizure Monitor Alarm System Market are increasing occurrence of epilepsy, growing alertness of the patients about seizure monitor alarm systems, and per head earnings.

Key Points: 
  • The important motivators of the Epileptic Seizure Monitor Alarm System Market are increasing occurrence of epilepsy, growing alertness of the patients about seizure monitor alarm systems, and per head earnings.
  • The global Epileptic Seizure Monitor Alarm System Market can be classified by Application, Product, Delivery System, End Users, and Region.
  • By End Users, Epileptic Seizure Monitor Alarm System Market can be classified as Online Pharmacy, E-commerce, Drug Stores, and Pharmacy Stores.
  • Access 109 page research report with TOC on "Epileptic Seizure Monitor Alarm System Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/2013-2028-report-on-global-epil...
    Some of the important companies for Epileptic Seizure Monitor Alarm System Market are Smart Monitor, Brain Sentinel, Danish Care, Alert-it, Empatica Inc., HI pass Design LLC, Med page Ltd., Vahlkamp, and Emfit Ltd., MC10 Inc., and others.

Epileptic Seizure Monitor Alarm System Market, 2028 - Challenges and Opportunity Worldwide; Key Players Profiled: Empatica, Emfit, Alert-it, Vahlkamp, Danish Care and Medpage | Radiant Insights, Inc.

Retrieved on: 
Monday, January 20, 2020
Medicine, Clinical medicine, Epileptic seizure, RTT, Health, Epilepsy

The important motivators of the Epileptic Seizure Monitor Alarm System Market are increasing occurrence of epilepsy, growing alertness of the patients about seizure monitor alarm systems, and per head earnings.

Key Points: 
  • The important motivators of the Epileptic Seizure Monitor Alarm System Market are increasing occurrence of epilepsy, growing alertness of the patients about seizure monitor alarm systems, and per head earnings.
  • The global Epileptic Seizure Monitor Alarm System Market can be classified by Application, Product, Delivery System, End Users, and Region.
  • By End Users, Epileptic Seizure Monitor Alarm System Market can be classified as Online Pharmacy, E-commerce, Drug Stores, and Pharmacy Stores.
  • Access 109 page research report with TOC on "Epileptic Seizure Monitor Alarm System Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/2013-2028-report-on-global-epil...
    Some of the important companies for Epileptic Seizure Monitor Alarm System Market are Smart Monitor, Brain Sentinel, Danish Care, Alert-it, Empatica Inc., HI pass Design LLC, Med page Ltd., Vahlkamp, and Emfit Ltd., MC10 Inc., and others.

Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

Retrieved on: 
Wednesday, January 8, 2020
Medicine, Clinical medicine, Health, Epilepsy, Medical genetics, Epileptic seizure, Genetic testing

"Behind the Seizure is one of the longest-running cross-company collaborations aimed at increasing access to genetic testing.

Key Points: 
  • "Behind the Seizure is one of the longest-running cross-company collaborations aimed at increasing access to genetic testing.
  • Early genetic testing may be the most cost-effective, direct and accurate diagnostic tool for children, shortening years-long diagnostic odysseys.
  • Behind the Seizure is an innovative, cross-company collaboration designed to increase access to genetic testing for children who experience unprovoked seizures in childhood in the United States and Canada.
  • 1 Miller, Nicole, et al, "Behind the Seizure: A No-Cost 125-gene Epilepsy Panel for Pediatric Seizure Onset Between 24 Years".

Invitae Announces Program with BioMarin to Expand Access to Genetic Testing for Skeletal Dysplasias

Retrieved on: 
Tuesday, December 10, 2019
Medicine, Clinical medicine, Health, Medical genetics, Rare diseases, BioMarin Pharmaceutical, Virotherapy, Genetic testing, Epilepsy, Epileptic seizure, Osteochondrodysplasia

We are pleased to collaborate with BioMarin on this program to increase access to genetic testing for patients."

Key Points: 
  • We are pleased to collaborate with BioMarin on this program to increase access to genetic testing for patients."
  • BioMarin and Invitae are committed to helping shorten the diagnostic odyssey for patients and families living with skeletal dysplasias.
  • The companies also created Behind the Seizure, a program that expands access to genetic testing for children with epilepsy.
  • Invitae sponsored testing programs are designed to increase access to genetic testing, particularly in conditions where earlier testing can improve diagnosis and treatment yet testing remains underutilized.

Lower Hospitalization Rates Seen Among Epilepsy Patients Treated with FYCOMPA® and Select Anti-Epileptic Drug (AED) Combinations

Retrieved on: 
Monday, December 9, 2019
Epilepsy, RTT, Anticonvulsants, Health, Medicine, Clinical medicine, GABAA receptor positive allosteric modulators, Epileptic seizure, Epilepsy in animals, SV2A

The study followed patients 12 years who were treated with select AED treatment combinations, classified into three groups: FYCOMPA+ sodium channel blocker (SC), SC+SC and SC+synaptic vesicle protein 2A binding (SV2).

Key Points: 
  • The study followed patients 12 years who were treated with select AED treatment combinations, classified into three groups: FYCOMPA+ sodium channel blocker (SC), SC+SC and SC+synaptic vesicle protein 2A binding (SV2).
  • In 2015, it was approved as adjunctive therapy for PGTC seizures in patients with epilepsy 12 years and older.
  • To date, FYCOMPA is approved in 55 countries and has been used to treat more than 200,000 patients worldwide across all indications.
  • Physicians are advised to recommend that pregnant patients taking FYCOMPA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.

Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting

Retrieved on: 
Monday, December 9, 2019
Research, Mental health, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Branches of biology, Ion channels, Proteins, RTT, KvLQT2, M current, Epileptic seizure, Epilepsy

The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development.

Key Points: 
  • The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development.
  • Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE.
  • Nanomolar brain concentrations of KB-3061 conferred significant seizure protection in the maximal electroshock model (MES) of epilepsy with minimal impact on neurobehavior.
  • Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with AES Annual Meeting news and updates using the hashtag #AES2019.

Aptar’s Nasal Unidose Device Approved by U.S. FDA for First Nasal Rescue Treatment for Frequent Seizure Activity

Retrieved on: 
Monday, December 9, 2019
Other Manufacturing, Medical devices, FDA, Packaging, Manufacturing, Other Health, Health, Pharmaceutical, General Health, Clinical medicine, Medicine, Health, RTT, Epileptic seizure, Nasal administration

This ready-to-use rescue treatment can be used when and where a seizure cluster occurs thanks to Aptars proven, intuitive and convenient Unidose Liquid System.

Key Points: 
  • This ready-to-use rescue treatment can be used when and where a seizure cluster occurs thanks to Aptars proven, intuitive and convenient Unidose Liquid System.
  • Aptars Unidose and Bidose platforms are robust, primeless, and intuitive systems with 360 functionality and precise nasal drug delivery.
  • This innovative rescue treatment for seizure activity is an example of a Combination Product submission, and benefited from Aptar Pharmas services offering, a comprehensive portfolio of stage-specific development packages.
  • The launch of our Unidose System on the first and only U.S. FDA approved nasal rescue treatment for seizure activity once again demonstrates Aptar Pharmas ability to help our customers develop and launch complex treatments, stated Gael Touya, President, Aptar Pharma.